Related Experiment Videos
Bone marrow transplantation in hemopoietic malignancies
1Ontario Cancer Institute, University of Toronto, Canada.
Current Opinion in Oncology
|April 1, 1991
Summary
Allogeneic bone marrow transplantation shows promise for improving survival in certain blood cancers. Advances in managing complications and understanding immune responses are key to its success, particularly in chronic myeloid leukemia.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Allogeneic bone marrow transplantation (BMT) has seen survival improvements due to better management of transplant-related complications.
- Disease control in BMT involves preparative regimens and immune surveillance mechanisms involving graft-derived cells.
Purpose of the Study:
- To explore the mechanisms of disease control in allogeneic bone marrow transplantation.
- To evaluate the risk-to-benefit ratio of BMT in various hematologic malignancies.
Main Methods:
- Review of developments in prophylactic and therapeutic interventions for allogeneic BMT.
- Analysis of immunologic interactions between tumor cells and graft-derived immune cells.
- Evaluation of patient outcomes in different hematologic malignancies.
Main Results:
- Chronic myeloid leukemia patients in the chronic phase demonstrate an optimal risk-to-benefit ratio for BMT.
- Recent data suggest BMT may be a preferred treatment for acute myeloid leukemia in first remission.
- BMT's role is less established for acute lymphoblastic leukemia, chronic lymphocytic leukemia, and malignant lymphoma.
Conclusions:
- Manipulating immune surveillance mechanisms could enhance understanding and application of BMT.
- Allogeneic BMT is a highly effective treatment for specific hematologic malignancies, with evolving indications.